• Transcode Therapeutics outlined three oncology platforms, led by tumor-targeted RNA therapeutics, alongside vaccine immunotherapies, immuno-oncolytic agents.
• Lead candidate TTX-MC138, a microRNA-10b antagomiR delivered via iron oxide nanoparticles, is in an active Phase 2a program.
• Phase 1a in advanced solid tumors: 16 patients treated, about 86 doses, no dose-limiting toxicities through 4.8 mg/kg.
• Efficacy signals: 9 of 14 evaluable patients had stable disease; 0 complete responses; 0 partial responses; 3 progressive disease.
• Funding profile: about USD 100 million net invested since the 2021 IPO through financings and grants; no long-term debt.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief on June 18, 2026, and is solely responsible for the information contained therein.